The schizophrenia risk gene MIR137 acts as a hippocampal gene network node orchestrating the expression of genes relevant to nervous system development and function

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 73, Issue , 2017, Pages 109-118

  Olde Loohuis, Nikkie F M ^a,b   Nadif Kasri, Nael ^a,b   Glennon, Jeffrey C ^a,b   van Bokhoven, Hans ^a,b   Hébert, Sébastien S ^c,d   Kaplan, Barry B ^e   Martens, Gerard J M ^b,f   Aschrafi, Armaz ^b,e  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY   (Netherlands)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^f RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Gene network; MicroRNA; Neurodevelopment

Indexed keywords

MICRORNA; MICRORNA 137; UNCLASSIFIED DRUG; MESSENGER RNA; MIRN137 MICRORNA, HUMAN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; COGNITION; CONTROLLED STUDY; EMBRYO; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE ONTOLOGY; HIPPOCAMPUS; LOSS OF FUNCTION MUTATION; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM FUNCTION; NEXT GENERATION SEQUENCING; NONHUMAN; PATHOPHYSIOLOGY; RAT; SCHIZOPHRENIA; ANIMAL; CELL CULTURE; CYTOLOGY; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC TRANSFECTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEK293 CELL LINE; HUMAN; MAMMALIAN EMBRYO; METABOLISM; NERVE CELL; NERVOUS SYSTEM; PATHOLOGY; WISTAR RAT;

ANIMALS; CELLS, CULTURED; EMBRYO, MAMMALIAN; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE ONTOLOGY; GENE REGULATORY NETWORKS; HEK293 CELLS; HIPPOCAMPUS; HUMANS; MICRORNAS; NERVOUS SYSTEM; NEURONS; RATS; RATS, WISTAR; RNA, MESSENGER; SCHIZOPHRENIA; TRANSFECTION;

EID: 84959496426     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2016.02.009     Document Type: Article

References (70)

1. Aschrafi, A., Cunningham, B.A., Edelman, G.M., Vanderklish, P.W., The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain 8. Proc. Natl. Acad. Sci. U. S. A. 102:6 (2005), 2180–2185.
2. Aschrafi, A., Schwechter, A.D., Mameza, M.G., Natera-Naranjo, O., Gioio, A.E., Kaplan, B.B., MicroRNA-338 regulates local cytochrome c oxidase IV mRNA levels and oxidative phosphorylation in the axons of sympathetic neurons. J. Neurosci. 28:47 (2008), 12581–12590 (Nov 19).
3. Baulcombe, D., RNA silencing in plants. Nature 431:7006 (2004), 356–363.
4. Chan, W.L., Holstein-Rathlou, N.H., Yip, K.P., Integrin mobilizes intracellular Ca(2 +) in renal vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 280:3 (2001), C593–C603 (Mar).
5. Chan, C.S., Weeber, E.J., Zong, L., Fuchs, E., Sweatt, J.D., Davis, R.L., Beta 1-integrins are required for hippocampal AMPA receptor-dependent synaptic transmission, synaptic plasticity, and working memory. J. Neurosci. 26:1 (2006), 223–232 (Jan 4).
6. Collins, A.L., Kim, Y., Bloom, R.J., Kelada, S.N., Sethupathy, P., Sullivan, P.F., Transcriptional targets of the schizophrenia risk gene MIR137. Transl. Psychiatry, 4, 2014, e404.
7. Crisafulli, C., Drago, A., Calabro, M., Spina, E., Serretti, A., A molecular pathway analysis informs the genetic background at risk for schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 59 (2015), 21–30 (Jun 3).
8. Dityatev, A., Schachner, M., Sonderegger, P., The dual role of the extracellular matrix in synaptic plasticity and homeostasis. Nat. Rev. Neurosci. 11:11 (2010), 735–746 (Nov).
9. Duygu, B., de Windt, L.J., da Costa Martins, P.A., Targeting microRNAs in heart failure. Trends Cardiovasc. Med., 2015 (May 30).
10. Dweep, H., Sticht, C., Pandey, P., Gretz, N., miRWalk—database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J. Biomed. Inform. 44:5 (2011), 839–847 (Oct).
11. Edbauer, D., Neilson, J.R., Foster, K.A., et al. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron 65:3 (2010), 373–384.
12. Evans, A.R., Euteneuer, S., Chavez, E., Mullen, L.M., Hui, E.E., Bhatia, S.N., Ryan, A.F., Laminin and fibronectin modulate inner ear spiral ganglion neurite outgrowth in an in vitro alternate choice assay. Dev. Neurobiol. 67:13 (2007), 1721–1730 (Nov).
13. Fan, Y., Abrahamsen, G., Mills, R., et al. Focal adhesion dynamics are altered in schizophrenia. Biol. Psychiatry 74:6 (2013), 418–426 (Sep 15).
14. Fan, H.M., Sun, X.Y., Niu, W., et al. Altered microRNA expression in peripheral blood mononuclear cells from young patients with schizophrenia. J. Mol. Neurosci. 56:3 (2015), 562–571 (Jul).
15. Fukao, A., Mishima, Y., Takizawa, N., et al. MicroRNAs trigger dissociation of eIF4AI and eIF4AII from target mRNAs in humans. Mol. Cell 56:1 (2014), 79–89 (Oct 2).
16. Funk, A.J., McCullumsmith, R.E., Haroutunian, V., Meador-Woodruff, J.H., Abnormal activity of the MAPK- and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia. Neuropsychopharmacology 37:4 (2012), 896–905 (Mar).
17. Gardel, M.L., Schneider, I.C., Aratyn-Schaus, Y., Waterman, C.M., Mechanical integration of actin and adhesion dynamics in cell migration. Annu. Rev. Cell Dev. Biol. 26 (2010), 315–333.
18. Gardiner, E., Beveridge, N.J., Wu, J.Q., Carr, V., Scott, R.J., Tooney, P.A., Cairns, M.J., Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol. Psychiatry 17:8 (2012), 827–840 (Jul).
19. Gomez, T.M., Letourneau, P.C., Filopodia initiate choices made by sensory neuron growth cones at laminin/fibronectin borders in vitro. J. Neurosci. 14:10 (1994), 5959–5972 (Oct).
20. Green, M.J., Cairns, M.J., Wu, J., et al. Genome-wide supported variant MIR137 and severe negative symptoms predict membership of an impaired cognitive subtype of schizophrenia. Mol. Psychiatry 18:7 (2013), 774–780 (Jul).
21. Guella, I., Sequeira, A., Rollins, B., et al. Evidence of allelic imbalance in the schizophrenia susceptibility gene ZNF804A in human dorsolateral prefrontal cortex. Schizophr. Res. 152:1 (2014), 111–116 (Jan).
22. Gui, P., Wu, X., Ling, S., et al. Integrin receptor activation triggers converging regulation of Cav1.2 calcium channels by c-Src and protein kinase A pathways. J. Biol. Chem. 281:20 (2006), 14015–14025 (May 19).
23. Helwak, A., Kudla, G., Dudnakova, T., Tollervey, D., Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell 153:3 (2013), 654–665 (Apr 25).
24. Hill, M.J., Donocik, J.G., Nuamah, R.A., Mein, C.A., Sainz-Fuertes, R., Bray, N.J., Transcriptional consequences of schizophrenia candidate miR-137 manipulation in human neural progenitor cells. Schizophr. Res. 153:1–3 (2014), 225–230 (Mar).
25. Huang da, W., Sherman, B.T., Lempicki, R.A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4:1 (2009), 44–57.
26. Janssen, H.L., Reesink, H.W., Lawitz, E.J., et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368:18 (2013), 1685–1694 (May 2).
27. John, B., Enright, A.J., Aravin, A., Tuschl, T., Sander, C., Marks, D.S., Human microRNA targets. PLoS Biol., 2(11), 2004, e363 (Nov).
28. Kim, A.H., Parker, E.K., Williamson, V., McMichael, G.O., Fanous, A.H., Vladimirov, V.I., Experimental validation of candidate schizophrenia gene ZNF804A as target for hsa-miR-137. Schizophr. Res. 141:1 (2012), 60–64 (Oct).
29. Kos, A., Aschrafi, A., Nadif Kasri, N., The multifarious hippocampal functions of microRNA-137. Neuroscientist, 2015 (Sep 22).
30. Kuswanto, C.N., Sum, M.Y., Qiu, A., Sitoh, Y.Y., Liu, J., Sim, K., The impact of genome wide supported microRNA-137 (MIR137) risk variants on frontal and striatal white matter integrity, neurocognitive functioning, and negative symptoms in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 168B:5 (2015), 317–326 (Jul).
31. Kwon, E., Wang, W., Tsai, L.H., Validation of schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 as miR-137 targets. Mol. Psychiatry 18:1 (2013), 11–12 (Jan).
32. Kyosseva, S.V., Differential expression of mitogen-activated protein kinases and immediate early genes fos and jun in thalamus in schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28:6 (2004), 997–1006 (Sep).
33. Kyosseva, S.V., Elbein, A.D., Griffin, W.S., Mrak, R.E., Lyon, M., Karson, C.N., Mitogen-activated protein kinases in schizophrenia. Biol. Psychiatry 46:5 (1999), 689–696 (Sep 1).
34. Kyosseva, S.V., Elbein, A.D., Hutton, T.L., Griffin, S.T., Mrak, R.E., Sturner, W.Q., Karson, C.N., Increased levels of transcription factors Elk-1, cyclic adenosine monophosphate response element-binding protein, and activating transcription factor 2 in the cerebellar vermis of schizophrenic patients. Arch. Gen. Psychiatry 57:7 (2000), 685–691 (Jul).
35. Lamprecht, R., The actin cytoskeleton in memory formation. Prog. Neurobiol. 117 (2014), 1–19 (Jun).
36. Lang, B., Pu, J., Hunter, I., et al. Recurrent deletions of ULK4 in schizophrenia: a gene crucial for neuritogenesis and neuronal motility. J. Cell Sci. 127:Pt 3 (2014), 630–640 (Feb 1).
37. Lewis, B.P., Burge, C.B., Bartel, D.P., Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:1 (2005), 15–20.
38. Liang, H., Li, W.H., MicroRNA regulation of human protein protein interaction network. RNA 13:9 (2007), 1402–1408 (Sep).
39. Magen, I., Hornstein, E., Oligonucleotide-based therapy for neurodegenerative diseases. Brain Res. 1584 (2014), 116–128 (Oct 10).
40. McKerracher, L., Chamoux, M., Arregui, C.O., Role of laminin and integrin interactions in growth cone guidance. Mol. Neurobiol. 12:2 (1996), 95–116 (Apr).
41. Miller, T.M., Pestronk, A., David, W., et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 12:5 (2013), 435–442 (May).
42. Nadif Kasri, N., Nakano-Kobayashi, A., Malinow, R., Li, B., Van Aelst, L., The Rho-linked mental retardation protein oligophrenin-1 controls synapse maturation and plasticity by stabilizing AMPA receptors. Genes Dev. 23:11 (2009), 1289–1302 (Jun 1).
43. Nadif Kasri, N., Nakano-Kobayashi, A., Van Aelst, L., Rapid synthesis of the X-linked mental retardation protein OPHN1 mediates mGluR-dependent LTD through interaction with the endocytic machinery. Neuron 72:2 (2011), 300–315 (Oct 20).
44. Olde Loohuis, N.F., Kos, A., Martens, G.J., Van Bokhoven, H., Nadif Kasri, N., Aschrafi, A., MicroRNA networks direct neuronal development and plasticity. Cell. Mol. Life Sci. 69:1 (2012), 89–102 (Jan).
45. Olde Loohuis, N.F., Ba, W., Stoerchel, P.H., et al. MicroRNA-137 controls AMPA-receptor-mediated transmission and mGluR-dependent LTD. Cell Rep. 11:12 (2015), 1876–1884 (Jun 30).
46. Pietersen, C.Y., Mauney, S.A., Kim, S.S., et al. Molecular profiles of pyramidal neurons in the superior temporal cortex in schizophrenia. J. Neurogenet. 28:1–2 (2014), 53–69 (Mar-Jun).
47. Ripke, S., O'Dushlaine, C., Chambert, K., et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat. Genet. 45:10 (2013), 1150–1159 (Oct).
48. Schizophrenia Psychiatric Genome-Wide Association Study C, Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 43:10 (2011), 969–976 (Oct).
49. Schwab, R., Palatnik, J.F., Riester, M., Schommer, C., Schmid, M., Weigel, D., Specific effects of microRNAs on the plant transcriptome. Dev. Cell 8:4 (2005), 517–527 (Apr).
50. Shi, W., Du, J., Qi, Y., et al. Aberrant expression of serum miRNAs in schizophrenia. J. Psychiatr. Res. 46:2 (2012), 198–204 (Feb).
51. Siegert, S., Seo, J., Kwon, E.J., et al. The schizophrenia risk gene product miR-137 alters presynaptic plasticity. Nat. Neurosci., 2015 (May 25).
52. Smrt, R.D., Szulwach, K.E., Pfeiffer, R.L., et al. MicroRNA miR-137 regulates neuronal maturation by targeting ubiquitin ligase mind bomb-1. Stem Cells 28:6 (2010), 1060–1070.
53. Spillane, M., Gallo, G., Involvement of Rho-family GTPases in axon branching. Small GTPases, 5, 2014, e27974.
54. Sun, X.Y., Zhang, J., Niu, W., et al. A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 168B:3 (2015), 170–178 (Apr).
55. Szulwach, K.E., Li, X., Smrt, R.D., et al. Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J. Cell Biol. 189:1 (2010), 127–141 (Apr 5).
56. Todorova, V.K., Elbein, A.D., Kyosseva, S.V., Increased expression of c-Jun transcription factor in cerebellar vermis of patients with schizophrenia. Neuropsychopharmacology 28:8 (2003), 1506–1514 (Aug).
57. van de Vondervoort II, Gordebeke, P.M., Khoshab, N., Tiesinga, P.H., Buitelaar, J.K., Kozicz, T., Aschrafi, A., Glennon, J.C., Long non-coding RNAs in neurodevelopmental disorders. Front. Mol. Neurosci., 6, 2013, 53.
58. Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., Speleman, F., Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol., 3(7), 2002 (RESEARCH0034, Jun 18).
59. Wang, X., miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA 14:6 (2008), 1012–1017 (Jun).
60. Wang, X., El Naqa, I.M., Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics 24:3 (2008), 325–332 (Feb 1).
61. Wang, X., Li, Y., Xu, X., Wang, Y.H., Toward a system-level understanding of microRNA pathway via mathematical modeling. Biosystems 100:1 (2010), 31–38 (Apr).
62. Willemsen, M.H., Valles, A., Kirkels, L.A., et al. Chromosome 1p21.3 microdeletions comprising DPYD and MIR137 are associated with intellectual disability. J. Med. Genet. 48:12 (2011), 810–818 (Dec).
63. Witwer, K.W., Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin. Chem. 61:1 (2015), 56–63 (Jan).
64. Wright, C., Turner, J.A., Calhoun, V.D., Perrone-Bizzozero, N., Potential impact of miR-137 and its targets in schizophrenia. Front. Genet., 4, 2013, 58.
65. Wright, C., Calhoun, V.D., Ehrlich, S., Wang, L., Turner, J.A., Bizzozero, N.I., Meta gene set enrichment analyses link miR-137-regulated pathways with schizophrenia risk. Front. Genet., 6, 2015, 147.
66. Wu, X., Reddy, D.S., Integrins as receptor targets for neurological disorders. Pharmacol. Ther. 134:1 (2012), 68–81 (Apr).
67. Wu, X., Davis, G.E., Meininger, G.A., Wilson, E., Davis, M.J., Regulation of the L-type calcium channel by alpha 5beta 1 integrin requires signaling between focal adhesion proteins. J. Biol. Chem. 276:32 (2001), 30285–30292 (Aug 10).
68. Xu, B., Hsu, P.K., Stark, K.L., Karayiorgou, M., Gogos, J.A., Derepression of a neuronal inhibitor due to miRNA dysregulation in a schizophrenia-related microdeletion. Cell 152:1–2 (2013), 262–275 (Jan 17).
69. Yu, H.C., Wu, J., Zhang, H.X., et al. Alterations of miR-132 are novel diagnostic biomarkers in peripheral blood of schizophrenia patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 63 (2015), 23–29 (Dec 3).
70. Yuan, P., Zhou, R., Wang, Y., Li, X., Li, J., Chen, G., Guitart, X., Manji, H.K., Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. J. Affect. Disord. 124:1–2 (2010), 164–169 (Jul).